Group One Trading
PHAS

Group One Trading’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Group One Trading’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$13K – 8848
2022
Q1 		$13K Sell
10,000
-4,000
-29% -$6.48K ﹤0.01% 7068
2021
Q4 		$37K Buy
14,000
+7,000
+100% +$21.2K ﹤0.01% 6557
2021
Q3 		$22K Buy
7,000
+5,500
+367% +$18.4K ﹤0.01% 7130
2021
Q2 		$6K Buy
+1,500
New +$4.99K ﹤0.01% 7732

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Group One Trading's PHAS Position: Q4 2021 in Review

Group One Trading sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 1,700 shares — an estimated $5.14K sold.

Group One Trading first reported a position in PHAS in Q4 2020 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

  • Group One Trading reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Group One Trading sold 1,700 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $5.14K.
  • Group One Trading first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Group One Trading's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $5K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Group One Trading's 13F filing for Q4 2021, filed 11 Feb 2022.